Robert E. Landry - Jan 12, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Jan 12, 2024
Transactions value $
-$224,022
Form type
4
Date filed
1/17/2024, 04:03 PM
Previous filing
Jan 8, 2024
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $303K +800 +3.54% $378.98 23.4K Jan 12, 2024 Direct
transaction REGN Common Stock Tax liability -$527K -568 -2.43% $928.18 22.8K Jan 12, 2024 Direct
holding REGN Common Stock 270 Jan 12, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -800 -5.17% $0.00 14.7K Jan 12, 2024 Common Stock 800 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.